The coronary stent market in India has reached a crucial milestone, with a valuation of USD 843.8 million in 2023, reflecting a transformative shift in the country’s approach to cardiovascular ...

NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has announced its financial results for 2024, alongside major ...

To accelerate potential completion of ongoing partnership restructuring negotiations, Orchestra BioMed and Terumo have elected to enter a mediation process and are currently working on a procedural ...

Patients who have a stent implanted to open a blocked coronary artery face dual risks of developing blood clots and of having excessive bleeding in the months following the procedure. While ...

March 27, 2025—Investigators seeking to compare real-world outcomes with drug-eluting stents (DES) in symptomatic femoropopliteal lesions have shared ... the lack of core laboratory review of ...

[34] Follow-up analysis demonstrated binary restenosis in 22% of BMS and 6% of PES patients (p = 0.021). By IVUS at 6 months, the percentage of neointimal volume obstruction was reduced with PES ...

The 1-year rate of in-stent restenosis (ISR) was 23.4% (15/64). The rate of ISR in Mori C lesions (53.8%, 7/13) was significantly higher than that in Mori A (15.8%, 3/19) or Mori B lesions (15.6%, ...

Whether the long-term benefit of stroke prevention when stenting is added to medical therapy (MT) over MT alone for symptomatic severe intracranial artery stenosis offsets the perioperative risks of ...

Rate of Stent Thrombosis With Drug-Eluting vs Bare-Metal Stents ACC.07: This large, real-world experience suggests that a follow-up period of 12 months after drug-eluting stent implantation may be ...